MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study

MorphoSys U.S., a fully owned subsidiary of MorphoSys (MOR), and Incyte (INCY) announced final five-year follow-up data from the Phase 2 L-MIND study showing that Monjuvi plus lenalidomide followed by Monjuvi monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma. At the data cut-off for the full analysis set, the overall response rate was 57.5%, and a complete response was observed in 41.2% of patients. A partial response was observed in 16.2% of patients. No new safety signals were identified. The majority of adverse events were grade 1 or grade 2 during both combination and monotherapy treatment. Patients experienced a lower frequency of all-grade and grade 3 or higher adverse events during monotherapy. The most common adverse events with combination therapy were neutropenia and thrombocytopenia, which declined after patients switched to monotherapy. Neutropenia and diarrhea were the most common adverse events in the first two years of monotherapy.